Metabolic profile of a new immunosuppressive agent, oxisuran: binding, RE stimulation, drug interaction.
D000818:Animals; D001711:Biotransformation; D002003:Brucella abortus / Q000276:immunology; D002250:Carbon Radioisotopes; D002855:Chromatography, Thin Layer; D004054:Diethylstilbestrol / Q000494:pharmacology; D004285:Dogs; D004731:Endotoxins / Q000494:pharmacology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism*; D051379:Mice; D008862:Microsomes, Liver; D010084:Oxidation-Reduction; D010424:Pentobarbital / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects; D010634:Phenobarbital / Q000494:pharmacology; D011485:Protein Binding; D011725:Pyridines / Q000378:metabolism* / Q000494:pharmacology / Q000652:urine; D051381:Rats; D012890:Sleep / Q000187:drug effects; D013434:Sulfenic Acids / Q000378:metabolism
D002250:Carbon Radioisotopes; D004731:Endotoxins; D007166:Immunosuppressive Agents; D011725:Pyridines; D013434:Sulfenic Acids; D004054:Diethylstilbestrol; D010424:Pentobarbital; D010634:Phenobarbital